ANI Pharmaceuticals, Inc. P/E Ratio 2009–2025
ANI Pharmaceuticals, Inc. reported 23.78 of price-to-earnings ratio for fiscal 2025. That was 63.3% lower than fiscal 2023. Compared with fiscal 2019, the change was -80.7%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 23.78 | — |
| FY 2024 | — | — |
| FY 2023 | 64.87 | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | 123.34 | +256.2% |
| FY 2018 | 34.63 | — |
| FY 2017 | — | — |
| FY 2016 | 178.29 | +421.5% |
| FY 2015 | 34.19 | +57.0% |
| FY 2014 | 21.77 | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: ANI Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ANIP 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ANI Pharmaceuticals, Inc. reported 23.78 of price-to-earnings ratio for fiscal 2025. That was 63.3% lower than fiscal 2023. Compared with fiscal 2019, the change was -80.7%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ANI Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeANI Pharmaceuticals, Inc. — frequently asked questions
What is ANI Pharmaceuticals, Inc.'s price-to-earnings ratio?
ANI Pharmaceuticals, Inc. (ANIP) reported price-to-earnings ratio of 23.78 for fiscal year 2025, per its SEC filings.
How has ANI Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, ANIP's price-to-earnings ratio grew at roughly 0.6% per year (compound annual rate), from 21.77 to 23.78.
Where does this data come from?
Figures are computed from ANI Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More ANIP financial history
Full ANIP fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →